Therefore, we assessed the effect of combination treatment on T-helper lymphocytes (CD4+), cytotoxic lymphocytes (CD8+), activated lymphocytes (Granzyme B+), and antitumor macrophages (CD86 positive M1 type macrophages) infiltrating tumor tissue (Fig. 5). This evidence concerns the gene CD8A and neoplasm.